

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Org. Biomol. Chem.*, 2024, **22**, 3249

Synthetic access to diverse thiazetidines *via* a one-pot microwave assisted telescopic approach and their interaction with biomolecules†

Ramdas Nishanth Rao,^a Soumyadip Das,^a Kezia Jacob,^a Mohammed Mujahid Alam,^c M. M. Balamurali ^{*d} and Kaushik Chanda ^{*a,b}

A one-pot microwave assisted telescopic approach is reported for the chemo-selective synthesis of substituted 1,3-thiazetidines using readily available 2-aminopyridines/pyrazines/pyrimidine, substituted isothiocyanates and 1,2-dihalomethanes. The procedure involves thiourea formation from 2-aminopyridines/pyrazines/pyrimidine with the substituted isothiocyanates followed by a base catalysed nucleophilic attack of the C=S bond on the 1,2-dihalomethane. Subsequently, a cyclization reaction occurs to yield substituted 1,3-thiazetidines. These four membered strained ring systems are reported to possess broad substrate scope with high functional group tolerance. The above synthetic sequence for the formation of four membered heterocycles is proven to be a modular and straightforward approach. Further the mechanistic pathway for the formation of 1,3-thiazetidines was supported by computational evaluations and X-ray crystallography analyses. The relevance of these thiazetidines in biological applications is evaluated by studying their ability to bind bio-macromolecules like proteins and nucleic acids.

Received 15th January 2024,
Accepted 22nd March 2024

DOI: 10.1039/d4ob00075g

rsc.li/obc

Introduction

Heterocyclic compounds have been extensively utilized in the development of numerous pharmaceuticals, agrochemicals, dyes and plastics.¹ The versatile nature of these heterocycles permits possible modifications for various applications *via* simple chemical reactions. Almost one third of the marketed drugs are heterocyclic that serve as important pharmacophore.² They also possess excellent photophysical properties that lead to their utilization for bio-imaging and other interdisciplinary applications.³ Most importantly, they are basic components of nucleic acids as purines and pyrimidines, and can significantly influence a wide range of biological activities as modulators and inhibitors in the form of bicyclic,⁴ polycyclic⁵ and organometallic complexes.⁶ Recently, various chemical

methodologies for the synthesis of heterocyclic compounds were reviewed for their potential biological interest such as nanoparticle catalyzed synthesis,⁷ ionic liquid mediated synthesis,⁸ microwave and water assisted methodologies,⁹ *etc.*

Among the various heterocyclic compounds, either natural or synthetic, four membered heterocyclic rings have their own significance. They belong to the 'small ring' group with a wide range of biological activities including anti-depressant,¹⁰ analgesic,¹¹ ACP reductase¹² activity, *etc.* Well known anti-bacterials like penicillin and cephalosporin contain a four membered β -lactam ring as their key structural element.¹³ The strained internal angle of 90° in four membered rings deviates significantly from the ideal bond angle of 109.5° for sp³ hybridized carbon. Conformational changes in the ring system induced by the observed steric repulsions of various substituents result in them possessing 'wing-shaped' orientations. Regarding their potency as anti-bacterial agents, most of the four membered rings suffer the drawbacks of anti-bacterial resistance and bond angle conformations that make them less stable molecules. In this regard, investigations are required to identify new four membered rings with hybrid modifications that can further add to the library of already existing stable structures. One such moiety is 1,3-thiazetidine containing one sulphur atom in addition to a nitrogen atom at the 1st and 3rd positions of the ring. The four-membered 1,3-thiazetidines also serve as important precursors with a broad range of therapeutic activities like anti-viral (A), pesticidal (B) and anti-bacterial (C) as shown in Fig. 1.¹⁴

^aDepartment of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, India. E-mail: chandakaushik1@gmail.com

^bDepartment of Chemistry, Rabindranath Tagore University, Hojai 782435, Assam, India

^cDepartment of Chemistry, College of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia

^dChemistry Division, School of Advanced Sciences, Vellore Institute of Technology, Chennai, Tamil Nadu, 600027, India. E-mail: mmbala@gmail.com

†Electronic supplementary information (ESI) available: ¹H NMR, ¹³C NMR, IR and HRMS spectra of compounds **4**. ct-DNA and BSA binding assays for compounds **4**, and X-ray data of compound **4g**. CCDC 2130702. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4ob00075g>





Fig. 1 Pharmacologically important 1,3-thiazetidine derivatives.

Although thiazetidines are known for their significant roles in numerous chemical or pharmacological applications, their synthesis techniques are restricted. Unlike the case of 3-membered aziridines, addition of a sulphur atom to azetidines in place of a carbon atom would relieve the strain and the resulting thiazetidines are expected to display better reactivity. Recently, the updated synthetic advancement and reactivity of


strain driven azetidine heterocycles was reported by Szostak's group.¹⁵ Fig. 2 demonstrates the most recent methods employed for the synthesis of 1,3-thiazetidine rings. In 1970, Field *et al.* performed the 1,2-thiazetidine ring synthesis by chlorinating 2-tosylamidoethyl disulfide to form the corresponding sulfonyl chloride followed by its treatment with triethyl amine (Fig. 2, a).¹⁶ Further in 1990, Goto *et al.* demon-

1. Previous approaches


a) Field *et al.*, 1970




b) Goto *et al.*, 1990




c) Yadav *et al.*, 2011



d) Shao *et al.*, 2016



e) Sun *et al.*, 2016



2. Our Approach




Fig. 2 Various approaches for the synthesis of 1,3-thiazetidines.


strated the synthesis of 2-imino-1,3-thiazetidines from CS₂, dialkylcyanamide and benzylideneaniline under high pressure conditions (Fig. 2, b).¹⁷ Subsequently, in 2011, Yadav *et al.* performed the coupling of various aldehydes with *O,O*-diethyl hydrogen phosphorodithioate and aldimines in THF using sodium hydride as base to yield 1,3-thiazetidines (Fig. 2, c).¹⁸ Recently, the solvent effect on the synthesis of 1,3-thiazetidine derivatives was demonstrated by Shao *et al.* Using a polar protic solvent like ethanol, the reaction between phenylthioureas and 1,1-dichloro-2-nitroethene yielded 1,3-thiazetidines while the same reaction in the presence of a polar solvent like chloroform yielded 1,4,2-dithiazolidines (Fig. 2, d).¹⁹ In the same year, Sun *et al.* reported the NaH catalyzed synthesis of thiazetidines linked with benzimidazole moieties in 10 min under one-pot conditions in good yield. Subsequently, benzimidazole fused thiadiazines in appreciable yields were generated when Et₃N was used at room temperature for 30 min in acetone solvent *via* a stepwise protocol using thiourea as an intermediate (Fig. 2, e).²⁰

Moreover, most of the reported synthetic routes used high pressure, toxic gases and longer reaction times, and lack functional diversity. Herein the development of a new generation of heterocyclic scaffolds employing various synthetic techniques starting from 2-aminopyridine²¹ is reported for the first time for 2-aminopyridine/pyrimidine/pyrazine derived 1,3-thiazetidines. Further to tune the intrinsic properties of the above mentioned bioactive thiazetidines, a one-pot telescopic approach was employed to generate 1,3-thiazetidines using different electron donating and electron withdrawing groups at various positions and the products were investigated for their ability to interact with biomolecules.

The versatility of the one-pot telescopic approach has been well established for the synthesis of heterocyclic moieties and drugs over the past decades.²² This one-pot method avoids separation and purification of intermediates and provides high yields in a time efficient manner.²³ Recently, there has been huge demand for mild and eco-friendly reactions that use microwaves to avoid multistep synthetic sequences and longer reaction times. We have recently reported a one-pot telescopic approach for the chemo-selective synthesis of substituted benzo[*e*]pyrido/pyrazino/pyridazino[1,2-*b*][1,2,4]thiadiazine dioxides.²⁴ Herein, the use of dihalomethanes as one carbon units for the production of structurally diverse 1,3-thiazetidines *via* a one-pot microwave assisted telescopic approach is reported.

Results and discussion

Initially, a benchmark reaction was performed with 2-aminopyridine (**1a**) and phenyl isothiocyanate (**2a**) to obtain thiourea (**3a**) that could serve as a precursor for the synthesis of four membered 1,3-thiazetidines as depicted in Scheme 1. As expected, thiourea product (**3a**) was obtained in 95% yield under microwave irradiation for 4 min in DMSO solvent at 120 °C.



Scheme 1 Synthesis of thiourea intermediate **3a** by microwave irradiation.

Following the formation of the above thiourea intermediate (**3a**), further steps in the synthetic sequence involved the formation of the four membered 1,3-thiazetidine framework using a one carbon fragment electrophile, 1,2-diiodomethane, as template for the reaction with the thiourea intermediate (**3a**). Further evaluation of various key factors and optimization of the reaction conditions were carried out. Initially, the effect of base and solvent conditions was examined and the relevant data are compiled in Table 1. Particularly, the thiourea intermediate (**3a**) skeleton was oriented in such a way that there is a possibility of base mediated nucleophilic attack of the C=S bond on 1,2-diiodomethane followed by intramolecular ring closure reaction *via* the pyridine N atom or the aniline N atom generating two 1,3-thiazetidines **4a** and **4a'** as depicted in Fig. 3.

When compound **3a** was treated with 1,2-diiodomethane under neat conditions at room temperature, it did not yield the cyclised product **4a** or **4a'** (Table 1, entry 1). Moreover, heating the reaction mixture to 100 °C for 5 h or using Et₃N as base under refluxing EtOH solution also did not yield any cyclised product (Table 1, entries 2 and 3 respectively). However, upon changing the base to K₂CO₃, the same reaction under refluxing EtOH for 5 h resulted in the formation of product **4a** or **4a'** in 20% yield (Table 2, entry 4). Further to

Table 1 Optimization of the 1,3-thiazetidine ring formation reaction^a

Entry	Solvent	Base	Temperature	Time (h)	Yield ^c (%)
1	Neat	—	r.t.	5	0
2	Neat	—	100 °C	5	0
3	EtOH	Et ₃ N	Reflux	5	0
4	EtOH	K ₂ CO ₃	Reflux	5	20
5	DMF	K ₂ CO ₃	100 °C	5	25
6	CH ₃ CN	K ₂ CO ₃	Reflux	5	35
7	DMSO	K ₂ CO ₃	100 °C	5	65
8	DMSO	K ₂ CO ₃	MW ^b , 120 °C	0.12	90
9	DMSO	NaOH	MW ^b , 120 °C	0.12	65
10	DMSO	Et ₃ N	MW ^b , 120 °C	0.12	0
11	DMSO	Piperidine	MW ^b , 120 °C	0.12	0
12	DMSO	K ₂ CO ₃	MW ^b , 120 °C	0.12	90 ^d
13	DMSO	KOtBu	100 °C	5	60
14	DMSO	KOtBu	MW ^b , 120 °C	0.12	75
15	DMSO	Cs ₂ CO ₃	100 °C	5	0
16	DMSO	Cs ₂ CO ₃	MW ^b , 120 °C	0.12	0

^a Reaction was performed using **3a** (1 mmol), 1,2-diiodomethane (1.2 mmol), and base (1.1 mmol). ^b Microwave reactions were carried out in microwave model no. CATA R (Catalyst Systems, Pune) at a power of 28 watts. ^c Yield of the isolated product. ^d Reaction was carried out with 1,2-dibromomethane.




Fig. 3 Two different modes of 1,3-thiazetidine ring formation.

Table 2 One-pot telescopic approach to substituted 1,3-thiazetidines via a chemo-selective pathway^{a,b}

$\text{R}_1\text{---}\begin{array}{c} \text{Y} \\ \diagup \quad \diagdown \\ \text{N} \quad \text{X} \end{array}\text{---}\text{NH}_2 + \text{R}_2\text{NCS} \xrightarrow[120^\circ\text{C}, 4\text{ min}]{\text{DMSO, MW}}$		$\left[\text{R}_1\text{---}\begin{array}{c} \text{Y} \\ \diagup \quad \diagdown \\ \text{N} \quad \text{X} \end{array}\text{---}\text{NH} \text{---} \text{C}(=\text{S})\text{---}\text{R}_2 \right] \xrightarrow[120^\circ\text{C}, 7\text{--}10\text{ min}]{\text{DMSO, K}_2\text{CO}_3, \text{I-CH}_2\text{-I, MW}}$	
1	2	3 (not isolated)	4
$\text{X}=\text{C}, \text{N}; \text{Y}=\text{C}, \text{N}$			
4a, 90% 4b, 90% 4c, 91% 4d, 92% 4e, 94% 4f, 92% 4g, 91% 4h, 95% 4i, 96% 4j, 91%^j 4k, 92% 4l, 94% 4m, 91% 4n, 90% 4o, 95% 4p, 89% 4q, 87% 4r, 81%			

^a Reaction conditions: amines (1 mmol), substituted isothiocyanates (1 mmol), K₂CO₃ (1.1 mmol), 1,2-diiodomethane (1.2 mmol), and solvent DMSO (5 mL). ^b Isolated yield.

increase the yield of the desired 1,3-thiazetidines, the reaction was attempted in polar aprotic solvent (DMF) at 100 °C or in refluxing acetonitrile solution (Table 1, entries 5 and 6 respectively). However, no substantial increment in the product yield was observed. But interestingly, the yield of the product increased to 65% when the same reaction was performed in

DMSO at 100 °C for 5 h (Table 1, entry 7). Further increase in the yield of the product to 90% was observed when the reaction was carried out with microwave irradiation at 120 °C for 7 min (Table 1, entry 8). However, upon using NaOH as the base, under the same conditions (microwave irradiation), no significant increase in the yield of the product was noted

(Table 1, entry 9). Moreover, the application of mild bases such as triethylamine and piperidine also did not yield any product formation (Table 1, entries 10 and 11, respectively).

The subsequent use of 1,2-dibromomethane as the electrophile in the heterocyclization reaction did not lead to any significant changes in the outcome of the reaction (Table 1, entry 12) which clearly demonstrated the advantages of microwave irradiation in ring closure reactions. The use of strong bases such as KOtBu did not cause any substantial changes in the yield of the reaction (Table 1, entries 13 and 14, respectively) whereas the reaction didn't proceed at all in the presence of Cs₂CO₃ as base both under the conventional and microwave conditions (Table 1, entries 15 and 16, respectively). Further to ascertain the formation of compound **4a** over **4a'**, the newly formed product was isolated and subjected to spectroscopic analysis including regular proton NMR spectroscopy. It was noticed that peaks at 14.5 and 10.2 ppm correspond to two NH protons of thiourea intermediate **3a** in spectrum A of Fig. 4. Along with the emergence of five aromatic protons in the phenyl isothiocyanate moiety, the chemical shift of these two protons moved further downfield. Intermediate **3a** upon reacting with 1,2-diiodomethane resulted in the formation of the thiazetidine **4a** or **4a'** which could not be confirmed through ¹H NMR spectra. In spectrum B (Fig. 4), the loss of two NH protons and the emergence of one singlet at 4.9 ppm confirms the formation of the desired four membered thiazetidine **4a** or **4a'**.

Since it was not possible to ascertain the formation of **4a** or **4a'** by regular proton NMR spectroscopy, computational investigations were attempted to get mechanistic details on the reaction process. The computational approaches involved the optimization of geometry using density functional theory and the B3LYP hybrid functional with the 6-311G++** basis set in their ground states.²⁵ The potential energy profile was created using the same technique to follow the mechanistic pathways (concerted/path 1/path 2) that result in the generation of product **4a** or **4a'** (Fig. 5).

The results of geometry optimization revealed that the strain induced by the approach of 1,2-dibromomethane increased the dihedral angle between the pyridine and the phenyl ring from 24.6° to 44.5° upon deprotonation of the pyridyl amine and to 41.9° for the aniline moiety. Further, upon cyclization to form product **4a** or **4a'**, the dihedral angle between >C=S and the pyridine ring was reduced from 36.8° to 1.6° and for the phenyl ring it was decreased to 9.9°. The above observations revealed that the reaction proceeds *via* geometry alterations to overcome the steric strain.

In order to ascertain the attainment of minimum energy structures, frequency calculations were carried out to ensure the absence of any negative frequencies. Further to identify the high energy structures of the transition states, force constants were evaluated applying the same functional and basis set as were used for geometry optimizations. The possible formation of products **4a** or **4a'** can be proposed to proceed




Fig. 4 Stepwise monitoring of (A) thiourea and (B) 1,3-thiazetidine ring formation **4a** or **4a'** formation by ¹H NMR spectroscopy.




Fig. 5 Geometry optimized structures of intermediates, transition states and corresponding products.

through two different mechanisms – (i) a concerted mechanism wherein the abstraction of the proton from the pyridine amine/aniline amine occurs simultaneously with the attack of $\text{CH}_2\text{-Br}$, and (ii) sequential abstraction of protons followed by the attack of $\text{CH}_2\text{-Br}$. The concerted mechanism with a trimolecular process involving simultaneous deprotonation and $\text{S}_{\text{N}}2$ substitution is entropically not likely. Therefore, a sequential reaction is expected. In this, the intermediate $3\text{a}_1'$ was found to possess $10.05 \text{ kcal mol}^{-1}$ lower energy than 3a_1 while the

two transition states, **ts** and **ts'** ($0.20 \text{ kcal mol}^{-1}$) were revealed to possess almost similar energies. Moreover in the sequential mechanism, two pathways can be proposed – abstraction from the pyridine amine -NH (path 1) and the aniline -NH (path 2). As shown in Fig. 6, path 1 involves the nucleophilic attack of the $\text{C}=\text{S}$ bond on 1,2-dihalomethane to produce the transition state **ts**, which is accomplished by the abstraction of the proton by the base from the pyridine amine nitrogen. While in path 2, the nucleophilic attack of the $\text{C}=\text{S}$ bond on the 1,2-dibromomethane, followed by the nucleophilic abstraction of the proton from the aniline nitrogen results in the formation of intermediate **ts'**.

The energy profile for the reaction is depicted in Fig. 7. The energy barrier for the conversion of 3a_1 to **4a** is $30.94 \text{ kcal mol}^{-1}$ and for $3\text{a}_1'$ to **4a'** it is $40.79 \text{ kcal mol}^{-1}$. This shows that the attainment of equilibrium is energetically more favourable in the former case (3a_1 to **4a**). Moreover, the energy required for the reverse reaction is 35.41 and $32.73 \text{ kcal mol}^{-1}$, respectively. Further, to ascertain the preference for pyridine amine proton abstraction over aniline amine proton abstraction and *vice versa*, in the sequential mechanism the abstraction of the aniline amine proton is energetically more favoured by $8.25 \text{ kcal mol}^{-1}$ than that of the pyridine amine proton




Fig. 6 Mechanistic investigation for the possible formation of products **4a** and **4a'**.




Fig. 7 Energy profile depicting the reaction coordinate for the conversion of intermediates to products.

(18.30 kcal mol⁻¹). It is known that pyridine >N–H is more acidic than aniline >N–H. In fact, aniline >N–H is more nucleophilic than pyridine >N–H. In this case, the chemo-selectivity is controlled by the acidity of pyridine >N–H and higher nucleophilicity of aniline >N–H. The calculated energetics revealed the possibility for the formation of product **4a** over **4a'**. Finally it has been established that the 1,3-thiazetidine ring formation by the attack on the aniline nitrogen is favoured rather than on the pyridyl amine nitrogen as depicted in Fig. 7 because the amidic resonance of anilides is much higher than that of pyridyl-amides.²⁶ The formation of product **4a** was further confirmed with the crystal structure data obtained for pyrazine derivative **4g** (Fig. 8 and the ESI†).

To further confirm the formation of 1,3-thiazetidine **4a**, the X-ray crystallographic study of compound **4g** was carried out. Fig. 8 depicts the ORTEP diagram of compound **4g** (X-ray crys-





Fig. 8 ORTEP diagram of compound **4g** with 40% thermal ellipsoid probability.

tallographic data given in the ESI†). The X-ray crystal structure of compound **4g** indicates exclusively the formation of the 1,3-thiazetidine ring that is favoured by the attack on the aniline nitrogen rather than on the pyridyl amine nitrogen atom, which unequivocally confirms its structure.²⁷


After successfully executing the 1,3-thiazetidine ring **4** formation, efforts to achieve the chemo-selective synthetic manipulation were attempted. For this reason, a one-pot telescopic reaction was performed, where the reaction of substituted 2-aminopyridines **1** with substituted isothiocyanates **2** under microwave irradiation for 4 min at 120 °C in DMSO solvent resulted in the formation of thioureas **3**. Without isolating the intermediate products **3**, the same reaction mixtures were subjected to microwave irradiation for 7 to 10 min at 120 °C with *in situ* addition of 1,2-diiodomethane and K₂CO₃ to obtain the desired 1,3-thiazetidine derivatives as depicted in Scheme 2.

Upon completion of the reaction, the ¹H NMR spectra of the synthesized compounds indicated the formation of pure 1,3-thiazetidines **4** in excellent yields. Further efforts to expand the substrate scope, to include 2-amino pyrimidine and 2-aminopyridazine as appropriate substrates were attempted in order to assess the effectiveness of the one-pot telescopic technique and to swiftly increase the size of the unique chemical library. As depicted in Table 2, a smooth transformation of 2-aminopyrimidine and 2-aminopyridazine to unique four membered 1,3-thiazetidine moieties was observed in excellent yields. Interestingly, using aniline as one of the components in the one-pot telescopic approach did not yield any 1,3-thiazetidine compound.

Finally, the corresponding 1,3-thiazetidine derivatives **4** were successfully produced through the telescopic reaction in excellent yields. This was followed by straightforward work-up procedures that involved the removal of solvent under reduced pressure, extraction and solvent evaporation procedures. Finally, the pure products were obtained after purifying through column chromatography, which was followed by the spectroscopic analysis of the pure compounds using ¹H NMR and ¹³C NMR spectroscopy, mass spectrometry (MS) and IR spectroscopy. The above model reaction was also successfully attempted for gram scale synthetic applicability following this one-pot telescopic method. According to Scheme 3, the reaction produced 2.05 g of **4a** in 85% yield with no appreciable loss in efficiency, highlighting the potential use of the current technique for large-scale synthesis of the scaffold 1,3-thiazetidine derivatives.



Scheme 2 One-pot telescopic approach to synthesize substituted 1,3-thiazetidines via a chemo-selective pathway.



Scheme 3 Gram-scale synthesis of 1,3-thiazetidine via a chemo-selective pathway.

Interaction studies of various 1,3-thiazetidine derivatives with bio-macromolecules

In order to evaluate the biological significance and potential of various synthesized thiazetidine derivatives, their interaction with calf thymus DNA (ct-DNA) and bovine serum albumin (BSA) protein was evaluated by following their electronic absorption and fluorescence spectra, respectively.²⁸ The equilibrium binding constant, number of binding sites and Stern–Volmer quenching constants were calculated following their interaction profiles.²⁹

BSA binding interactions. Albumins are known to be present in abundant quantities in plasma and serve as carriers for many drug molecules. The structural and physiological characteristics of these proteins make them a suitable agent for drug delivery applications. Albumins have very good biocompatibility, biodegradability, non-immunogenicity and bio-safety for numerous clinical applications. In order to investigate the performance of the herein reported thiazetidines in biological systems, their interactions with BSA protein were followed as described elsewhere with slight modifications.^{30,35} The observed fluorescence emission from any protein is due to the presence of amino acids like phenylalanine, tyrosine and tryptophan.^{31,32} In order to follow the protein's interaction and its mechanism, fluorescence spectral titrations were carried out at a fixed concentration of protein (20 μM). The samples were excited at 280 nm and the emission was monitored in the wavelength range of 285–500 nm. The sample (**4a–4p**) concentration was varied from 0–24 μM . The quenching of fluorescence intensity was monitored at 345 nm. A hypsochro-

mic shift of $\sim 3\text{--}5$ nm was observed in the emission spectra of the protein. The observed shift was mainly due to the binding of thiazetidine with the active sites of the protein in its hydrophobic environment. These results indicate that all the thiazetidine derivatives significantly bind to protein.

The fluorescence quenching interactions can be described by the Stern–Volmer equation (eqn (1)).

$$I_0/I = 1 + K_{\text{SV}}[Q] \quad (1)$$

where I_0 and I indicate the fluorescence intensities in the absence and presence of the thiazetidine derivative (quencher), respectively. K_{SV} is a linear Stern–Volmer quenching constant and $[Q]$ is the quencher concentration. The quenching constant was calculated using the plot of (I_0/I) versus $[Q]$ (Fig. 9) and relevant data are compiled in Table 3. When small molecules bind independently to a set of equivalent sites on a macromolecule, the equilibrium between free and bound molecules is represented by the Scatchard equation (eqn (2)).^{33,34} The effective binding of 1,3-thiazetidine derivatives with the protein was evaluated by applying the equation (eqn (2)) and the values of the binding constant along with the number of binding sites on the protein were also calculated (Table 3).

$$\log[(I_0 - I)/I] = \log K + n \log [Q] \quad (2)$$

Where I_0 and I are the fluorescence intensities in the absence and presence of quencher, K is the equilibrium binding constant, $[Q]$ is the concentration of the quencher and n is the number of equivalent binding sites on the macromolecule.




Fig. 9 (a) Stern–Volmer and (b) Scatchard plots to evaluate the quenching constant and binding constant for 1,3-thiazetidine derivative **4g**.

Table 3 Evaluated values of the Stern–Volmer quenching constant, the equilibrium binding constant and the number of binding sites on the protein

Entry	$K_{SV} \times 10^5 \text{ (M}^{-1}\text{)}$	$K \text{ (M}^{-1}\text{)}$	n
4a	0.768	5.20×10^6	1.3
4b	0.943	9.29×10^6	1.3
4c	0.571	9.28×10^5	1.2
4d	0.231	2.04×10^4	0.9
4e	0.360	5.23×10^5	1.2
4f	0.336	1.25×10^5	1.0
4g	2.087	6.05×10^8	1.3
4h	0.233	3.30×10^4	1.0
4i	0.329	2.80×10^4	0.9
4j	0.176	4.09×10^6	1.4
4k	0.429	3.64×10^6	1.3
4l	0.249	1.54×10^5	1.1
4m	0.106	4.72×10^5	1.3
4n	0.053	6.58×10^5	1.3
4o	0.161	2.65×10^4	1.0
4p	0.642	8.05×10^5	1.1
4q	0.300	0.02×10^6	0.97
4r	0.243	0.06×10^6	0.99

The data in Table 3 reveal that thiazetidine derivative **4g** binds more strongly to the protein with a binding constant of $6.05 \times 10^8 \text{ M}^{-1}$. In general it could be observed that electron donating groups like $-\text{CH}_3$ on the pyridyl/pyrimidyl/pyrazine ring lead to strong interaction with the protein while electron withdrawing groups like $-\text{Br}$ lead to a relatively weaker interaction. In addition to that, phenyl substitution on the thiazetidine nitrogen leads to a stronger binding interaction when compared to benzyl or alkyl substituents. Therefore, it could be the size or the steric effect that stabilizes the interactions in addition to the electronic effects as discussed above. Moreover, the quenching constant

values indicate that the intrinsic fluorescence from the amino acids including tryptophan, tyrosine and phenylalanine is quenched either by their exposure to solvent or through energy transfer to quencher molecules. The value of n indicates that there exists only one binding site offered by the protein for its interaction with thiazetidine derivatives.


Nucleic acid interaction. The capability of thiazetidines to target diseases at a genetic level can assist in preventing the expression of various disease causing proteins. The interactions of thiazetidine derivatives (**4a–4r**) with ct-DNA were monitored by recording the UV-Vis absorption spectra in the range of 220 to 380 nm as shown in Fig. 10. The presence of an isosbestic point in all the cases except compounds **4f**, **4g**, **4i** and **4m**, indicates the presence of an equilibrium between the nucleic acid bound and unbound forms of the thiazetidines.

The binding strength (K_b) values of complexes with ct-DNA were calculated by using the following equation.³⁶

$$[\text{DNA}]/(\epsilon_a - \epsilon_f) = [\text{DNA}]/(\epsilon_b - \epsilon_f) + 1/K_b(\epsilon_b - \epsilon_f) \quad (3)$$

Where $[\text{DNA}]$ is the concentration of the DNA in base pairs, the apparent absorption coefficients ϵ_a , ϵ_f and ϵ_b correspond to $A_{\text{obsd}}/[\text{complex}]$, the extinction coefficient for the complex in its free form and the extinction coefficient for the complex fully bound with DNA, respectively. The intrinsic binding constant (K_b) is obtained from the ratio of the slope to the intercept and the relevant data are given in Table 4.

From the data reported in Table 4, it is evident that derivatives **4b** and **4p** display exceptionally higher binding affinity as compared to the others (Table 5). In most of the cases, a stronger interaction was observed when an alkyl substituent was present on the pyridine ring. Not limited to the above, the geo-

**Fig. 10** UV-Vis absorption spectra depicting the interaction of calf thymus DNA with 1,3-thiazetidine derivatives **4b** and **4p**.**Table 4** The values of binding constants for various 1,3-thiazetidine derivatives (**4a–4r**) with ct-DNA obtained by spectrophotometric assay

Entry	$K_b \text{ (M}^{-1}\text{)}$	Entry	$K_b \text{ (M}^{-1}\text{)}$	Entry	$K_b \text{ (M}^{-1}\text{)}$	Entry	$K_b \text{ (M}^{-1}\text{)}$
4a	3.20×10^4	4e	4.46×10^4	4i	7.02×10^4	4m	8.29×10^4
4b	1.42×10^5	4f	7.46×10^3	4j	4.13×10^3	4n	2.48×10^4
4c	1.41×10^4	4g	2.45×10^4	4k	4.78×10^4	4o	3.36×10^4
4d	3.97×10^4	4h	5.13×10^3	4l	2.00×10^4	4p	1.35×10^5
4q	1.60×10^4	4r	2.70×10^4				

Table 5 Literature reported nucleic acid binding constants and quenching constants upon interaction with proteins for representative heterocyclic molecules

Heterocyclic compounds	DNA binding K_b (M^{-1})	Protein binding K_{sv} (M^{-1})	Literature report
	3.00×10^5	1.99×10^5	Ref. 37
	—	9.5×10^5	Ref. 24
	—	1.6×10^4	Ref. 38
	2.03×10^5	—	Ref. 39

metry and orientation of the molecule in the binding cavity of the macromolecule also plays a key role in determining the binding interactions. All these results indicate that the herein reported 1,3-thiazetidine derivatives possess significant nucleic acid interaction potential and hence can be utilized for their applications as biomolecular probes. Further development of this type of unique four membered ring compound might be of interest to medicinal chemists.

Conclusions

A microwave-assisted one-pot telescopic synthesis of diverse 1,3-thiazetidines *via* thiourea formation followed by the base catalysed nucleophilic addition of 1,2-diiodomethane with subsequent intramolecular cyclization is reported for the first time in the literature. With this protocol it is possible to synthesize efficiently, various diverse four membered 1,3-thiazetidines by taking advantage of the broad substrate scope and short reaction times with good to excellent yields. Further the mechanistic pathway was supported by DFT evaluations and X-ray crystallography. The biological significance of the synthesized 1,3-thiazetidines was evaluated by investigating their ability to bind biomacromolecules including proteins and nucleic acids. Compound **4g** exhibited efficient binding affinity with BSA protein while **4b** and **4p** revealed a relatively stronger interaction with ct-DNA as compared to all the other derivatives. Further, this study suggested that these unique four membered 1,3-thiazetidines might serve as potent candidates for biomolecular probes for drug discovery applications.

Experimental section

General methods

Unless otherwise indicated all common reagents and solvents were used as obtained from commercial suppliers without further purification. 1H NMR (400 MHz) and ^{13}C NMR (100 MHz) spectra were recorded on a Bruker DRX400 spectrometer. Chemical shifts are reported in ppm relative to the internal solvent peak. Coupling constants, J , are given in Hz. Multiplicities of peaks are given as: d (doublet), m (multiplet), s (singlet), and t (triplet). Mass spectra were recorded on a PerkinElmer Calrus 600 GC-MS spectrometer. HRMS spectra were recorded on an LC-QTOF-HRMS. IR spectra were recorded on a Bomen DA8 3FTS spectrometer. Microwave assisted reactions were carried out in a Catalyst Scientific Microwave oven system (Model No: CATA R (Catalyst System, Pune) operating at 2450 MHz equipped with glass vial extension by a condenser was used for performing the reaction. The microwave was equipped with a temperature control system (external probe). All the starting materials such as 2-aminopyridine, 2-aminopyrimidine, 2-aminopyridazine and substituted isothiocyanates were purchased from either Sigma-Aldrich or Avra Scientific Limited.

Representative procedure for the synthesis of (Z)-3-phenyl-N-(pyridin-2-yl)-1,3-thiazetidin-2-imine 4a. In a round bottomed flask, a mixture of 2-aminopyridine **1a** (0.1 g, 1.06 mmol, 1.0 equiv.) and phenyl isothiocyanate **2a** (0.144 g, 1.06 mmol, 1.0 equiv.) was added to 5 mL of DMSO. The reaction mixture was subjected to microwave irradiation at 280 watts for 4 min at 120 °C. The progress of the reaction was monitored by TLC.

After completion, to the same reaction mixture was added 1,2-diiodomethane (0.338 g, 1.27 mmol, 1.20 equiv.) and K_2CO_3 (0.160 g, 1.16 mmol, 1.1 equiv.) and the reaction mixture was subjected to microwave irradiation at 280 watts for 7 min at 120 °C. After checking the progress of the reaction by TLC, the reaction mixture was cooled to room temperature and the crude product was washed with water and extracted with ethyl acetate (10 mL, twice). The combined organic layer was dried over anhydrous $MgSO_4$. The combined filtrate was subjected to evaporation to obtain the crude compound, which was purified over a silica gel column (60–120 mesh) using 5% ethyl acetate in hexane as eluent to obtain (*Z*)-3-phenyl-*N*-(pyridin-2-yl)-1,3-thiazetidin-2-imine **4a** as the product.

Yield = 0.216 g, 90%; white solid; mp: 63–65 °C; R_f = 0.75 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.33 (d, J = 4 Hz, 1H), 7.62 (dd, J = 7.8, 6.7 Hz, 3H), 7.37 (t, J = 7.8 Hz, 2H), 7.10–7.04 (m, 2H), 6.92 (t, J = 6.2 Hz, 1H), 4.92 (s, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.9, 156.0, 146.6, 140.6, 137.8, 129.1, 122.9, 119.8, 118.4, 116.0, 50.9; MS (GC-MS) 241; HRMS (EI, m/z) calcd for $C_{13}H_{11}N_3S$: m/z 241.0674; found 241.0670; IR (cm^{-1} , KBr) 3049, 2875, 1550, 740, 680.

***N*-(3-Methylpyridin-2-yl)-3-phenyl-1,3-thiazetidin-2-imine (4b).** Yield = 0.229 g, 90%; white solid; mp: 49–51 °C; R_f = 0.6 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.18 (d, J = 4.56 Hz, 1H), 7.63 (d, J = 8.12 Hz, 2H), 7.46 (d, J = 7.8 Hz, 1H), 7.37 (t, J = 7.8 Hz, 2H), 7.06 (t, J = 7.3 Hz, 1H), 6.86 (dd, J = 7.4, 4.9 Hz, 1H), 4.92 (s, 2H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 158.3, 155.2, 143.8, 140.7, 138.2, 129.1, 127.7, 122.6, 118.3, 115.9, 51.0, 17.4; MS (GC-MS) 255; HRMS (EI, m/z) calcd for $C_{14}H_{13}N_3S$: m/z 255.0830; found 255.0828; IR (cm^{-1} , KBr) 3053, 2914, 1564, 742, 680.

(*Z*)-*N*-(4-Methylpyridin-2-yl)-3-phenyl-1,3-thiazetidin-2-imine (4c). Yield = 0.232 g, 91%; white solid; mp: 57–59 °C; R_f = 0.72 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.11 (d, J = 5.08 Hz, 1H), 7.54 (d, J = 7.84 Hz, 2H), 7.28 (t, J = 7.6 Hz, 2H), 6.98 (t, J = 7.36 Hz, 1H), 6.69 (d, J = 4 Hz, 1H), 6.86 (s, 1H), 4.83 (s, 2H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.9, 155.8, 149.0, 146.2, 140.6, 129.1, 122.8, 120.2, 119.7, 116.0, 50.8, 20.9; MS (GC-MS) 255; HRMS (EI, m/z) calcd for $C_{14}H_{13}N_3S$: m/z 255.0830; found 255.0827; IR (cm^{-1} , KBr) 2927, 1666, 1554, 738, 682.

***N*-(6-Methylpyridin-2-yl)-3-phenyl-1,3-thiazetidin-2-imine (4d).** Yield = 0.234 g, 92%; pale white solid; mp: 65–67 °C; R_f = 0.68 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 7.62 (d, J = 7.8 Hz, 2H), 7.50 (d, J = 7.68 Hz, 1H), 7.35 (t, J = 7.64 Hz, 2H), 7.04 (t, J = 7.52 Hz, 1H), 6.90 (d, J = 7.84 Hz, 1H), 6.77 (d, J = 7.36 Hz, 1H), 4.90 (s, 2H), 2.48 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.2, 156.2, 155.7, 140.7, 138.0, 129.2, 129.0, 122.7, 111.7, 116.5, 116.0, 51.3, 23.9; MS (GC-MS) 255; HRMS (EI, m/z) calcd for $C_{14}H_{13}N_3S$: m/z 255.0830; found 255.0827; IR (cm^{-1} , KBr) 3061, 2854, 1585, 746, 688.

***N*-(5-Bromopyridin-2-yl)-3-phenyl-1,3-thiazetidin-2-imine (4e).** Yield = 0.298 g, 94%; light white solid; mp: 113–115 °C; R_f = 0.75 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.35 (s, 1H), 7.70 (dd, J = 8.6, 2.6 Hz, 1H), 7.60 (d, J = 7.92 Hz, 2H), 7.36 (t, J = 7.72 Hz, 2H), 7.07 (t, J = 7.36 Hz, 1H), 6.98 (d, J =

8.52 Hz, 1H), 4.91 (s, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 158.6, 156.6, 147.4, 140.4, 140.3, 129.1, 123.1, 121.1, 116.1, 113.7, 50.8; MS (GC-MS) 318; HRMS (EI, m/z) calcd for $C_{13}H_{10}BrN_3S$: m/z 318.9779; found 318.9776; IR (cm^{-1} , KBr) 3041, 1629, 1558, 740, 684, 630.

3-Phenyl-*N*-(pyrimidin-2-yl)-1,3-thiazetidin-2-imine (4f). Yield = 0.222 g, 92%; white solid; mp: 98–100 °C; R_f = 0.5 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $DMSO-d_6$) δ 9.05 (s, 1H), 7.87 (d, J = 7.76 Hz, 3H), 7.69 (t, J = 7.6 Hz, 3H), 7.38 (t, J = 7.28 Hz, 1H), 2.92 (s, 2H); ^{13}C NMR (100 MHz, $DMSO-d_6$) δ 157.7, 144.9, 134.3, 133.9, 127.0, 123.5, 123.4, 35.8; MS (GC-MS) 242; HRMS (EI, m/z) calcd for $C_{12}H_{10}N_3S$: m/z 242.0626; found 242.0624; IR (cm^{-1} , KBr) 3041, 1629, 1558, 740, 684, 630.

3-Phenyl-*N*-(pyrazin-2-yl)-1,3-thiazetidin-2-imine (4g). Yield = 0.220 g, 91%; off white solid; mp: 95–97 °C; R_f = 0.69 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.42 (s, 1H), 8.23 (s, 1H), 8.15 (d, J = 2.6 Hz, 1H), 7.61 (d, J = 8.4 Hz, 2H), 7.38 (t, J = 8 Hz, 2H), 7.09 (t, J = 7.44 Hz, 1H), 4.94 (s, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 157.9, 156.3, 142.7, 140.8, 140.1, 138.2, 129.2, 123.5, 116.2, 50.7; MS (GC-MS) 242; HRMS (EI, m/z) calcd for $C_{12}H_{10}N_4S$: m/z 242.0626; found 242.0627; IR (cm^{-1} , KBr) 3041, 2872, 1627, 738, 684.

***N*-(Pyridin-2-yl)-3-(*p*-tolyl)-1,3-thiazetidin-2-imine (4h).** Yield = 0.242 g, 95%; white solid; mp: 110–112 °C; R_f = 0.78 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.31 (d, J = 6.16 Hz, 1H), 7.60 (t, J = 7.96 Hz, 1H), 7.50 (d, J = 8.46 Hz, 2H), 7.15 (d, J = 8.28 Hz, 2H), 7.07 (dd, J = 8.1, 1.0 Hz, 1H), 6.90 (dd, J = 7.3, 1.0 Hz, 1H), 4.89 (s, 2H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.0, 155.8, 146.6, 138.3, 137.7, 132.4, 129.5, 119.7, 118.2, 116.1, 50.9, 20.8; MS (GC-MS) 255; HRMS (EI, m/z) calcd for $C_{14}H_{13}N_3S$: m/z 255.0830; found 255.0838; IR (cm^{-1} , KBr) 3282, 2137, 1548, 893, 750.

***N*-(3-Methylpyridin-2-yl)-3-(*p*-tolyl)-1,3-thiazetidin-2-imine (4i).** Yield = 0.255 g, 95%; white solid; mp: 135–136 °C; R_f = 0.59 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.17 (d, J = 3.76 Hz, 1H), 7.53 (d, J = 8.44 Hz, 2H), 7.45 (d, J = 7.28 Hz, 1H), 7.17 (d, J = 8.36 Hz, 2H), 6.84 (dd, J = 7.40, 4.92 Hz, 1H), 4.90 (s, 2H), 2.38 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 158.5, 155.0, 143.8, 138.5, 138.1, 132.1, 129.5, 127.6, 118.1, 115.8, 51.0, 20.8, 17.4; MS (GC-MS) 269; HRMS (EI, m/z) calcd for $C_{15}H_{15}N_3S$: m/z 269.0987; found 269.0985; IR (cm^{-1} , KBr) 3047, 2731, 1588, 804, 779.

***N*-(4-Methylpyridin-2-yl)-3-(*p*-tolyl)-1,3-thiazetidin-2-imine (4j).** Yield = 0.244 g, 91%; white solid; mp: 130–132 °C; R_f = 0.71 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 8.17 (d, J = 5.04 Hz, 1H), 7.49 (d, J = 7.84 Hz, 2H), 7.15 (d, J = 7.96 Hz, 2H), 6.91 (s, 1H), 6.74 (d, J = 5 Hz, 1H), 4.88 (s, 2H), 2.31 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.0, 155.7, 148.9, 146.2, 138.4, 132.3, 129.5, 120.1, 119.6, 116.0, 50.8, 20.9, 20.8; MS (GC-MS) 269; HRMS (EI, m/z) calcd for $C_{15}H_{15}N_3S$: m/z 269.0987; found 269.0985; IR (cm^{-1} , KBr) 3028, 2852, 1589, 821, 804.

***N*-(6-Methylpyridin-2-yl)-3-(*p*-tolyl)-1,3-thiazetidin-2-imine (4k).** Yield = 0.247 g, 92%; white solid; mp: 127–129 °C; R_f = 0.73 (10% EtOAc/*n*-hexane); 1H NMR (400 MHz, $CDCl_3$) δ 7.51–7.47 (m, 3H), 7.14 (d, J = 8.28 Hz, 2H), 6.88 (d, J = 7.92 Hz, 1H), 6.76

(d, $J = 7.4$ Hz, 1H), 4.87 (s, 2H), 2.40 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.3, 156.1, 155.7, 138.4, 138.0, 132.3, 117.5, 116.4, 116.1, 51.3, 23.9, 20.8; MS (GC-MS) 269; HRMS (EI, m/z) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{S}$: m/z 269.0987; found 269.0984; IR (cm^{-1} , KBr) 3026, 2860, 1554, 810, 786.

3-Benzyl-*N*-(pyridin-2-yl)-1,3-thiazetidin-2-imine (4l). Yield = 0.239 g, 94%; white solid; mp: 110–112 °C; $R_f = 0.69$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, $J = 4.92$ Hz, 1H), 7.93 (d, $J = 8.36$ Hz, 1H), 7.53 (dd, $J = 8.7$, 1.9 Hz, 1H), 7.31–7.24 (m, 4H), 7.17 (dd, $J = 7.72$, 1H), 6.81 (dd, $J = 7.3$, 1.1 Hz, 1H), 4.86 (s, 2H), 4.31 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.4, 147.8, 147.6, 139.7, 138.0, 128.4, 127.5, 126.8, 117.7, 113.1, 55.4, 43.8; MS (GC-MS) 255; HRMS (ESI, m/z) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_3\text{S}$: m/z 255.0830; found 255.0828; IR (cm^{-1} , KBr) 3026, 2870, 1496, 732, 694.

3-Benzyl-*N*-(6-methylpyridin-2-yl)-1,3-thiazetidin-2-imine (4m). Yield = 0.244 g, 91%; off white solid; mp: 98–100 °C; $R_f = 0.75$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 8.0 (d, $J = 4.76$ Hz, 1H), 7.75 (s, 1H), 7.31–7.24 (m, 4H) 7.17 (t, $J = 8.36$ Hz, 1H), 6.55 (dd, $J = 5.5$, 1.5 Hz, 1H), 4.84 (s, 2H), 4.31 (s, 2H) 2.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.5, 149.5, 148.0, 147.1, 139.7, 128.4, 127.5, 126.8, 119.1, 113.3, 55.5, 43.8, 21.3; MS (GC-MS) 269; HRMS (EI, m/z) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{S}$: m/z 269.0987; found 269.0984; IR (cm^{-1} , KBr) 2958, 2821, 1678, 813, 698.

3-Benzyl-*N*-(6-methylpyridin-2-yl)-1,3-thiazetidin-2-imine (4n). Yield = 0.242 g, 90%; pale yellow solid; mp: 97–99 °C; $R_f = 0.78$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 7.71 (d, $J = 8.2$ Hz, 1H), 7.41 (t, $J = 7.84$ Hz, 1H), 7.31–7.24 (m, 4H) 7.17 (t, $J = 6.68$ Hz, 1H), 6.66 (d, $J = 7.4$ Hz, 1H), 4.85 (s, 2H), 4.30 (s, 2H) 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.7, 150.8, 148.0, 139.8, 138.1, 128.3, 127.5, 126.8, 117.0, 109.7, 55.4, 43.8, 24.2; MS (GC-MS) 269; HRMS (EI, m/z) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{S}$: m/z 269.0987; found 269.0984; IR (cm^{-1} , KBr) 3024, 2819, 1672, 769, 700.

3-Butyl-*N*-(pyridin-2-yl)-1,3-thiazetidin-2-imine (4o). Yield = 0.209 g, 95%; white solid; mp: 80–82 °C; $R_f = 0.79$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 8.13 (d, $J = 4.96$ Hz, 1H), 7.85 (d, $J = 8.4$ Hz, 1H), 7.53 (dd, $J = 8.6$, 1.8 Hz, 1H), 6.80 (dd, $J = 7.31$, 1.1 Hz, 1H), 4.02 (s, 2H), 3.08 (t, $J = 6.84$ Hz, 2H) 1.56–1.49 (m, 2H), 1.37–1.32 (m, 2H), 0.87 (t, $J = 7.32$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.48, 146.5, 144.9, 136.9, 116.4, 111.8, 50.7, 42.6, 32.1, 19.4, 12.9; MS (GC-MS) 221; HRMS (EI, m/z) calcd for $\text{C}_{11}\text{H}_{15}\text{N}_3\text{S}$: m/z 221.0987; found 221.1022; IR (cm^{-1} , KBr) 3055, 1622, 1492, 740, 682, 499.

3-Butyl-*N*-(4-methylpyridin-2-yl)-1,3-thiazetidin-2-imine (4p). Yield = 0.209 g, 89%; white solid; mp: 93–95 °C; $R_f = 0.68$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 5.12$ Hz, 1H), 7.66 (s, 1H), 6.43 (dd, $J = 5.2$, 1.4 Hz, 1H), 4.79 (s, 2H), 3.07 (t, $J = 6.88$ Hz, 2H), 2.24 (s, 3H), 1.57–1.50 (m, 2H), 1.37–1.32 (m, 2H), 0.88 (t, $J = 7.32$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.6, 151.6, 149.3, 147.1, 146.1, 139.2, 135.2, 123.9, 123.4, 118.9, 115.6, 114.0, 113.0, 51.9, 43.6, 33.1, 22.3, 20.5, 13.9; MS (GC-MS) 235; HRMS (EI, m/z) calcd for $\text{C}_{12}\text{H}_{17}\text{N}_3\text{S}$: m/z 235.1143; found 235.1147; IR (cm^{-1} , KBr) 2958, 2926, 1708, 512, 669.

(*Z*)-3-(3,5-Dimethylphenyl)-*N*-(pyridin-2-yl)-1,3-thiazetidin-2-imine (4q). Yield = 0.234 g, 87%; white solid; mp: 115–117 °C; $R_f = 0.57$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 8.33 (dd, $J = 5.0$, 1.2 Hz, 1H), 7.65–7.61 (m, 1H), 7.24 (s, 2H), 7.11 (d, $J = 8.0$ Hz, 1H), 6.93 (dd, $J = 6.5$, 1.6 Hz, 1H), 6.71 (s, 1H), 4.91 (s, 2H), 2.34 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.1, 146.2, 140.4, 138.9, 138.1, 125.0, 119.5, 118.3, 113.9, 50.7, 21.5; MS (GC-MS) 269; HRMS (ESI, m/z) calcd for $\text{C}_{15}\text{H}_{16}\text{N}_3\text{S}$: 270.1065; found: 270.1065; IR (cm^{-1} , KBr) 2954, 2849, 1513, 1378, 1039, 834, 742.

(*Z*)-*N*-(Pyridin-2-yl)-3-(*o*-tolyl)-1,3-thiazetidin-2-imine (4r). Yield = 0.206 g, 81%; yellow viscous liquid; $R_f = 0.65$ (10% EtOAc/*n*-hexane); ^1H NMR (400 MHz, CDCl_3) δ 8.30 (dd, $J = 5.0$, 1.5 Hz, 1H), 7.55–7.51 (m, 1H), 7.46 (t, $J = 1.5$ Hz, 1H), 7.25–7.17 (m, 3H), 6.93 (d, $J = 8.0$ Hz, 1H), 6.87 (dd, $J = 6.0$, 1.6 Hz, 1H), 4.92 (s, 2H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.2, 159.0, 146.5, 138.5, 137.7, 134.0, 131.4, 127.4, 126.7, 125.2, 119.3, 118.0, 54.6, 29.7; MS (GC-MS) 255; HRMS (ESI, m/z) calcd for $\text{C}_{14}\text{H}_{14}\text{N}_3\text{S}$: 256.0908; found: 256.0908; IR (cm^{-1} , KBr) 2961, 1513, 1202, 777, 749, 551.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors thank the Chancellor and Vice Chancellor of Vellore Institute of Technology for providing the opportunity to carry out this study. Further, the authors wish to thank the management of this institute for providing seed money as a research grant. Thanks are also due to the Central Instrumentation Facility VIT for recording the spectra and for use of the single-crystal X-ray diffractometer. Mohammed Mujahid Alam is also grateful to the Deanship of Scientific Research, King Khalid University, for support through the Large Research Group Project number R.G.P. 2/210/1444. KC thanks the Vice Chancellor of Rabindranath Tagore University, Hojai for his keen interest in this work.

References

- 1 D. Ye, H. Lu, Y. He, J. Zheng, J. Wu and W. Hao, *Nat. Commun.*, 2022, **13**, 3337 and references cited therein.
- 2 (a) N. T. A. Dawoud, E. M. A. El-Fakharany, A. E. Hamada, E. I. Gendi and D. R. Lotfy, *Sci. Rep.*, 2022, **12**, 3424 and references cited therein. (b) D. C. Blakemore, L. Castro, I. Churcher, D. C. Rees, A. W. Thomas, D. M. Wilson and A. Wood, *Nat. Chem.*, 2018, **10**, 383–394.
- 3 (a) K. Chanda and M. M. Balamurali, *Chem. Soc. Rev.*, 2021, **50**, 3706–3719 and references cited therein. (b) S. Jena, B. Choudhury, M. G. Ahmad, M. M. Balamurali and K. Chanda, *Spectrochim. Acta, Part A*, 2023, **287**, 122081.

- 4 R. Kaur and K. Kumar, *Eur. J. Med. Chem.*, 2021, **215**, 113220.
- 5 L. M. De Coen, T. S. A. Heugebaert, D. García and C. V. Stevens, *Chem. Rev.*, 2016, **116**, 80–139.
- 6 (a) R. L. Panchangam, R. N. Rao, V. Manickam, M. M. Balamurali and K. Chanda, *Inorg. Chem.*, 2021, **60**, 17593; (b) T. S. Prathima, B. Choudhury, M. G. Ahmad, K. Chanda and M. M. Balamurali, *Coord. Chem. Rev.*, 2023, **490**, 215231.
- 7 S. Das and K. Chanda, *ChemNanoMat*, 2022, **8**, e202200375.
- 8 M. G. Ahmad and K. Chanda, *Coord. Chem. Rev.*, 2022, **472**, 214769.
- 9 R. N. Rao, S. Jena, M. Mukherjee, B. Maiti and K. Chanda, *Environ. Chem. Lett.*, 2021, **19**, 3315.
- 10 P. Melloni, A. D. Torre, M. Meroni, A. Ambrosini and A. C. Rossi, *J. Med. Chem.*, 1979, **22**, 183–191.
- 11 D. C. Bishop, J. F. Cavalla, I. M. Lockhart, M. Wright, C. V. Winder, A. Wong and M. Stephens, *J. Med. Chem.*, 1968, **11**, 466–470.
- 12 M. Takhi, K. Sreenivas, C. K. Reddy, M. Munikumar, K. Praveena, P. Sudheer, B. N. V. M. Rao, G. Ramakanth, J. Sivaranjani, S. Mulik, Y. R. Reddy, K. N. Rao, R. Pallavi, A. Lakshminarasimhan, S. K. Panigrahi, T. Antony, I. Abdullah, Y. K. Lee, M. Ramachandra, R. Yusof, N. A. Rahman and S. Hosahalli, *Eur. J. Med. Chem.*, 2014, **84**, 382–394.
- 13 K. Tahlan and S. E. Jensen, *J. Antibiot.*, 2013, **66**, 401–410.
- 14 (a) Q. Ding, N. Jiang and R. J. Weikert, Ativiral Compounds, WO2014135472A1, 2014; (b) E. W. Baum, G. D. Crouse, W. H. Dent, T. C. Sparks and L. C. Creemer, Pesticidal Compositions And Process Related Thereto, WO2013116052A1, 2013; (c) J. Segawa, M. Kitano, K. Kazuno, M. Matsuoka, I. Shirahase, M. Ozaki, M. Matsuda, Y. Tomii and M. Kise, *J. Med. Chem.*, 1992, **35**, 4727–4638; (d) Y. Takuji and M. Susumu, *Antimicrob. Agents Chemother.*, 1993, **37**, 793–800.
- 15 H. Mughal and M. Szostak, *Org. Biomol. Chem.*, 2021, **19**, 3274–3286.
- 16 N. E. Heimer and L. Field, *J. Org. Chem.*, 1970, **35**, 1668–1670.
- 17 T. Tohru, M. Yasumoto, I. Shibuya, Y. Taguchi, K. Yonemoto and M. Goto, *Chem. Lett.*, 1990, **19**, 1423–1426.
- 18 R. Ankita and L. D. S. Yadav, *Tetrahedron Lett.*, 2011, **52**, 3933–3936.
- 19 Y. Feng, M. Zou, R. Song, X. Shao, Z. Li and X. Qian, *J. Org. Chem.*, 2016, **81**, 10321–10327.
- 20 M. Selvaraju, S. Dhole and C. M. Sun, *J. Org. Chem.*, 2016, **81**, 8867–8875.
- 21 (a) R. N. Rao and K. Chanda, *Chem. Commun.*, 2022, **58**, 343–382; (b) U. Dasmahapatra, C. K. Kumar, S. Das, P. T. Subramanian, P. Murali, A. E. Isaac, K. Ramanathan, M. M. Balamurali and K. Chanda, *Front. Chem.*, 2022, **10**, 991369.
- 22 H. Ishikawa, T. Suzuki and Y. Hayashi, *Angew. Chem., Int. Ed.*, 2009, **48**, 1304–1307.
- 23 S. Das and K. Chanda, *Synthesis*, 2024, **56**, 693–699.
- 24 R. D. Padmaja, M. M. Balamurali and K. Chanda, *J. Org. Chem.*, 2019, **84**, 11382–11390.
- 25 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman and D. J. Fox, *Gaussian 09, revision B.01*, Gaussian, Inc., Wallingford, 2010.
- 26 (a) S. Shi and M. Szostak, *Org. Lett.*, 2017, **19**, 4656–4659; (b) R. Szostak, G. Meng and M. Szostak, *J. Org. Chem.*, 2017, **82**, 6373–6378.
- 27 Final product **4g** was crystallized by slow evaporation of its ethyl acetate–hexane (1 : 1, v/v) solution at room temperature. Crystal data: C₁₂H₁₀N₄S, *M* = 242.30, triclinic, space group *P*1. The crystal data has been deposited at Cambridge Crystallographic Data Centre [CCDC no. 2130702†].
- 28 S. U. Parsekar, K. Paliwal, P. Haldar, P. K. S. Antharjanam and M. Kumar, *ACS Omega*, 2022, **7**, 2881–2896.
- 29 F. Hashemi-Shahraki, B. Shareghi and S. Farhadian, *Int. J. Biol. Macromol.*, 2023, **227**, 1151–1161.
- 30 R. Lange, P. Anzenbacher, S. Muller, L. Maurin and C. Balny, *Eur. J. Biochem.*, 1994, **226**, 963–970.
- 31 F. I. Khan, M. T. Rehman, F. Sameena, T. Hussain, M. F. AlAjmi, D. Lai and M. K. A. Khan, *J. Mol. Recognit.*, 2022, **35**, e2958.
- 32 M. Makarska-Bialokoz, *Spectrochim. Acta, Part A*, 2018, **193**, 23–32.
- 33 G. Vignesh, S. Arunachalam, S. Vignesh and R. A. James, *Spectrochim. Acta, Part A*, 2012, **96**, 108–116.
- 34 S. L. Zhang, H. Yao, C. Wang and K. Y. Tam, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 4963–4968.
- 35 E. Lissi and E. Abuin, *J. Fluoresc.*, 2011, **21**, 1831–1833.
- 36 M. Feizi-Dehnayebi, E. Dehghanian and H. Mansouri-Torshizi, *J. Iran. Chem. Soc.*, 2022, **19**, 3155–3175.
- 37 T. Göktürk, E. S. Çetin, T. Hökelek, H. Pekel, Ö. Şensoy, E. N. Aksu and R. Güp, *ACS Omega*, 2023, **8**, 31839–31856.
- 38 B. C. Yallur, U. Katrahalli, P. M. Krishna and M. D. Hadagal, *Spectrochim. Acta, Part A*, 2019, **222**, 117192.
- 39 T. A. Farghaly, A. M. A. Alnaja, H. A. El-Ghamry and M. R. Shaaban, *Bioorg. Chem.*, 2020, **102**, 104103.